FimmCyte Therapeutics

FimmCyte is a Swiss biotech developing disease modifying therapies for chronic diseases through elimination of diseased cells directly. FimmCyte has a pipeline of multi-specifics with the two most advanced assets ready for IND and CMC for endometriosis and an organ fibrosis.

Date, time and room information

May 6, 12:45 - 13:00, room Singapore

Category
Emerging biotech company
Title of the presentation
Disease Modifying Therapies for Chronic Fibro-inflammatory Disease
Speaker information
Name Position Institution
Dr. Mohaned Shilaih CEO FimmCyte Therapeutics